Analysis of redox status and HDL subclasses in patients with lymphoma and the associations with FDG-PET/CT findings

被引:1
|
作者
Mirjanic-Azaric, Bosa [1 ,2 ]
Stankovic, Sinisa [3 ,4 ]
Nezic, Lana [5 ]
Radic Savic, Zana [1 ]
Malcic- Zanic, Dragana [6 ]
Skrbic, Ranko [5 ,7 ]
Kotur-Stevuljevic, Jelena [8 ]
Bogavac-Stanojevic, Natasa [8 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Biochem, Banja Luka, Bosnia & Herceg
[2] Univ Clin Ctr Republ Srpska, Inst Lab Diag, Banja Luka 78000, Bosnia & Herceg
[3] Univ Clin Ctr Republ Srpska, Internal Med, Banja Luka, Bosnia & Herceg
[4] Univ Banja Luka, Fac Med, Banja Luka, Bosnia & Herceg
[5] Univ Banja Luka, Fac Med, Dept Pharmacol Toxicol & Clin Pharmacol, Banja Luka, Bosnia & Herceg
[6] Univ Banja Luka, Fac Med, Dept Pediat, Banja Luka, Bosnia & Herceg
[7] Acad Sci & Arts Republ Srpska, Banja Luka, Bosnia & Herceg
[8] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
redox status; HDL subclasses; SUVmax; Hodgkin lymphoma; non-Hodgkin lymphoma; OXIDATION PROTEIN PRODUCTS; HEALTH-ORGANIZATION CLASSIFICATION; TOTAL OXIDANT/ANTIOXIDANT STATUS; HIGH-DENSITY-LIPOPROTEIN; HODGKIN-LYMPHOMA; STRESS; LDL; CHOLESTEROL; PON1; CHEMOTHERAPY;
D O I
10.3389/fonc.2023.1221414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Newer research points to alterations in the plasma redox status and the HDL subclass distributions in cancer. We aimed to assess the redox status and the HDL subclass distributions, lipids, and inflammatory markers in lymphoma patients in order to determine whether they were correlated with changes in FDG-PET/CT scans. At the beginning of this study, redox status, HDL subclasses, lipids, and inflammation biomarkers were determined in 58 patients with lymphoma (Hodgkin lymphoma, n=11 and non-Hodgkin lymphoma, n=47), and these same measurements were reassessed during their ensuing treatment (in 25 patients). Initially, the total oxidation status (TOS), the prooxidant-antioxidant balance (PAB), the OS index (OSI), the total protein sulfhydryl groups (SH-groups), and the advanced oxidation protein products (AOPP) were significantly higher in lymphoma patients as compared to healthy subjects, but the total antioxidant status (TAS) was significantly reduced. The PAB had a strong correlation with the CRP and interleukin-6 (rho=0.726, p<0.001; rho=0.386, p=0.003). The correlations between these parameters and the maximum standardized uptake values (SUVmax) were: PAB, rho=0.335 and p=0.010; SH-groups, rho=0.265 and p=0.044; CRP, rho=0.391 and p=0.002; HDL3b, rho=0.283 and p=0.031; HDL2b, rho= -0.294 and p=0.025; and HDL size, rho= -0.295 and p=0.024. The reductions in SUVmax between two follow-up points were associated with increases in the OSI, TOS, and SH-groups, as well as a reduction in the PAB and TAS. In conclusion, the redox parameters in patients with lymphoma were consistent with FDG-PET/CT findings. Targeting the redox status parameters and the HDL subclasses could be potential strategies in the molecular fight against lymphoma.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] FDG-PET scanning in managing patients with lymphoma
    Bodet-Milin, C.
    Salaun, P. -Y.
    Crespin, C.
    Vuillez, J. -P.
    Kraeber-Bodere, F.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2009, 33 (08): : 486 - 490
  • [2] FDG-PET scans in patients with lymphoma
    Elstrom R.L.
    Leonard J.P.
    Current Hematologic Malignancy Reports, 2008, 3 (4) : 197 - 203
  • [3] Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma
    Kazama, Toshiki
    Faria, Silvana C.
    Uchida, Yoshitaka
    Ito, Hisao
    Macapinlac, Homer A.
    ANNALS OF NUCLEAR MEDICINE, 2008, 22 (02) : 111 - 114
  • [4] Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma
    Toshiki Kazama
    Silvana C. Faria
    Yoshitaka Uchida
    Hisao Ito
    Homer A. Macapinlac
    Annals of Nuclear Medicine, 2008, 22 : 111 - 114
  • [5] Whole body FDG-PET/CT for the assessment of bone marrow infiltration in patients with newly diagnosed lymphoma
    Wang Xiao-Xue
    Huang Xinyue
    Zhang Lijun
    MEDICINA CLINICA, 2020, 154 (02): : 61 - 65
  • [6] Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma
    Drees, Esther E. E.
    Roemer, Margaretha G. M.
    Groenewegen, Nils J.
    Perez-Boza, Jennifer
    van Eijndhoven, Monique A. J.
    Prins, Leah I.
    Verkuijlen, Sandra A. W. M.
    Tran, Xuan-Mai
    Driessen, Julia
    Zwezerijnen, G. J. C.
    Stathi, Phylicia
    Mol, Kevin
    Karregat, Joey J. J. P.
    Kalantidou, Aikaterini
    Valles-Marti, Andrea
    Molenaar, T. J.
    Aparicio-Puerta, Ernesto
    van Dijk, Erik
    Ylstra, Bauke
    Groothuis-Oudshoorn, Catharina G. M.
    Hackenberg, Michael
    de Jong, Daphne
    Zijlstra, Josee M.
    Pegtel, D. Michiel
    JOURNAL OF EXTRACELLULAR VESICLES, 2021, 10 (09)
  • [7] FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma
    Gallamini, Andrea
    Kurlapski, Michal
    Zaucha, Jan Maciej
    CANCERS, 2021, 13 (16)
  • [8] Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT
    Herrmann, Ken
    Queiroz, Marcelo
    Huellner, Martin W.
    Barbosa, Felipe de Galiza
    Buck, Andreas
    Schaefer, Niklaus
    Stolzman, Paul
    Veit-Haibach, Patrick
    BMC CANCER, 2015, 15
  • [9] Is ceCT necessary beyond FDG-PET/CT for primary staging in Hodgkin lymphoma?
    Kornelia, Kajary
    Zsuzsa, Molnar
    Szabolcs, Szakall, Jr.
    Peter, Molnar
    Zsolt, Lengyel
    ORVOSI HETILAP, 2014, 155 (06) : 226 - 230
  • [10] FDG-PET/CT in Evaluation and Prognostication of Primary Prostate Lymphoma
    Hodgson, Richard
    Huang, Yi-Tung
    Steinke, Karin
    Kumar, Aravind S. Ravi
    CLINICAL NUCLEAR MEDICINE, 2010, 35 (06) : 418 - 420